Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PYX-201 monotherapy study in 2L and 3L HNSCC patients who are EGFR and PD-1 inhibitor experienced

Next Previous
X
Search
Trial Profile

PYX-201 monotherapy study in 2L and 3L HNSCC patients who are EGFR and PD-1 inhibitor experienced

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PYX-201 (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 19 Dec 2024 .According to Pyxis Oncology media release, patient dosing in this trial is expected to begin in early 2025.
    • 25 Nov 2024 New trial record
    • 20 Nov 2024 According to Pyxis Oncology media release, preliminary clinical data readout expected in first half of 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top